HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin.

AbstractBACKGROUND:
Qualitative differences in antithrombotic efficacy between thrombin inhibitors may be explained by the affinity for which they bind thrombin. This affinity is inversely proportional to the inhibitory constant for the agent (Ki). Thrombin inhibitors, DuP714 (Ki=10(-11)) and argatroban (Ki=10(-8)), were compared to our previous studies with r-hirudin (Ki=10(-13)).
METHODS AND RESULTS:
Prior to balloon angioplasty, thirty pigs randomly received DuP714 (0.1 mg/kg bolus and 0.6 mg/kg/h infusion; n=8), argatroban (0.2 mg/kg/min. continuous infusion; n=9), or saline (n=17). Injured arterial segments were measured for (111)In-platelet and 125I-fibrin(ogen) deposition and the incidence of macroscopic thrombus. In DuP714-treated animals, platelet and fibrin(ogen) deposition were significantly lower than controls in both carotid (10+/-2 vs. 62+/-18 and 20+/-4 vs. 74+/-6) and coronary (10+/-4 vs. 160+/-63 and 17+/-3 vs. 86+/-22) arteries (p<0.005). In contrast, platelet and fibrin(ogen) deposition were similar when comparing argatroban to saline in carotid (41+/-20 vs. 40+/-9 and 71+/-5 vs. 49+/-7) and coronary (92+/-33 vs. 151+/-45 and 114+/-37 vs. 89+/-38) arteries (p=0.82 and 0.38, respectively). Compared to argatroban, fibrin(ogen) (p<0.001) and coronary platelet deposition (p<0.05) were significantly reduced in animals treated with DuP714 with no significant difference in carotid platelet deposition (p=0.10). Neither inhibitor prevented macroscopic thrombosis. In previous studies with r-hirudin in this model, platelet deposition was limited to a monolayer with complete inhibition of macroscopic thrombus.
CONCLUSIONS:
Direct thrombin inhibitors do not equally prevent arterial thrombosis. Qualitative differences may be explained in part by the affinity for which they bind thrombin.
AuthorsRobert D McBane 2nd, Nancy L Hassinger, Jozef S Mruk, Diane E Grill, James H Chesebro
JournalThrombosis research (Thromb Res) Vol. 116 Issue 6 Pg. 525-32 ( 2005) ISSN: 0049-3848 [Print] United States
PMID16181988 (Publication Type: Comparative Study, Evaluation Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Anticoagulants
  • Boron Compounds
  • Hirudins
  • Oligopeptides
  • Pipecolic Acids
  • Recombinant Proteins
  • Sulfonamides
  • acetylphenylalanyl-prolyl-boroarginine
  • Arginine
  • Thrombin
  • argatroban
Topics
  • Angioplasty, Balloon
  • Animals
  • Anticoagulants (administration & dosage)
  • Arginine (analogs & derivatives)
  • Boron Compounds (pharmacology)
  • Drug Evaluation, Preclinical
  • Hirudins (administration & dosage)
  • Oligopeptides (pharmacology)
  • Pipecolic Acids (administration & dosage)
  • Recombinant Proteins (administration & dosage)
  • Sulfonamides
  • Swine
  • Thrombin (antagonists & inhibitors)
  • Thrombosis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: